Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Routes for Drug Delivery: Sustained-Release Devices.

Samuel Yun, John J Huang

    Developments in Ophthalmology
    |October 27, 2015
    PubMed
    Summary

    Explore sustained-release drug delivery technologies for retinal diseases. Approved options include implants, with newer biodegradable and encapsulated cell technologies offering flexible, prolonged drug release and combination therapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    <i>In vivo</i> cellular-resolution imaging of retina: modality, cells, and clinical implications.

    Frontiers in ophthalmology·2026
    Same author

    Repeat Conjunctival Biopsy after Immunomodulatory Therapy for Ocular Mucous Membrane Pemphigoid.

    Ocular immunology and inflammation·2016
    Same author

    Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

    Lancet (London, England)·2015
    Same author

    Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition.

    Lancet (London, England)·2015
    Same author

    Central retinal vein occlusion resulting from anomalous retinal vascular anatomy in a 24-year-old man.

    Clinical ophthalmology (Auckland, N.Z.)·2015
    Same author

    Intraocular metastasis of testicular natural killer T-cell lymphoma with diffuse retinal pigment epithelium changes.

    Retinal cases & brief reports·2014

    Area of Science:

    • Ophthalmology
    • Biomaterials Science
    • Drug Delivery Systems

    Background:

    • Several sustained-release drug delivery technologies are available for retinal diseases, including nonbiodegradable and biodegradable implants, micro/nanoparticles, liposomes, and encapsulated cell technology (ECT).
    • Current FDA-approved sustained-release devices for retinal conditions include ganciclovir and fluocinolone acetonide implants (nonbiodegradable, surgical placement) and a dexamethasone implant (biodegradable, injectable).

    Purpose of the Study:

    • To review existing and emerging sustained-release drug delivery technologies for retinal diseases.
    • To highlight the advantages and limitations of different delivery systems.
    • To discuss the potential of novel technologies for future therapeutic applications.

    Main Methods:

    • Literature review of sustained-release drug delivery systems for ophthalmic applications.
    • Analysis of currently approved sustained-release implants by the FDA.
    • Examination of emerging technologies such as micro/nanoparticles, liposomes, and ECT.

    Main Results:

    • Nonbiodegradable implants require surgery, while the biodegradable dexamethasone implant offers easier administration.
    • Encapsulated cell technology (ECT) is in clinical trials, using modified cells for in-situ drug production.
    • Microparticle, nanoparticle, and liposome technologies show promise for flexible, prolonged drug release and combination therapies.

    Conclusions:

    • Biodegradable implants and emerging technologies like micro/nanoparticles, liposomes, and ECT represent significant advancements in sustained drug delivery for retinal diseases.
    • These novel approaches offer greater flexibility, potential for combination therapy, and improved patient compliance compared to traditional nonbiodegradable implants.
    • Further development of these technologies is crucial for addressing unmet needs in managing chronic and complex retinal conditions.

    Related Experiment Videos